SALT LAKE CITY, Utah, May 14, 2020 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced that the first patient has been dosed with a one-hour dosing schedule for investigational agent alvocidib, a potent CDK9 inhibitor, administered in sequence after azacitidine, in the expansion of the Phase 1b/2 Zella 102 study in patients with myelodysplastic syndromes (MDS).
The Zella 102 study is being conducted in patients with previously untreated MDS and patients with MDS who have received fewer than six cycles of treatment with a hypomethylating agent. The initial study design was to evaluate the safety and efficacy of alvocidib using a 30-minute bolus followed by a four-hour intravenous infusion (IVI), in combination with decitabine. An amendment was made to the study design to include treatment with azacitidine, in sequence before a one-hour infusion of alvocidib.
"We are pleased that this study now includes both standard of care hypomethylating agents for patients with myelodysplastic syndromes. In addition, the expansion of this study offers an alternative alvocidib dosing schedule, which reduces the amount of time patients spend in infusion," said David J. Bearss, Ph.D., Chief Executive Officer, Tolero Pharmaceuticals, and Chief Scientific Officer and Global Head of Research, Global Oncology. "Preclinical research suggests that treatment with hypomethylating agents may sensitize MDS blast cells to suppression of MCL-1 through alvocidib. We look forward to building our understanding of the potential role of alvocidib in this patient population."
MDS is a form of cancer that can occur when cells in the bone marrow are abnormal and create defective blood cells, which often die earlier than normal cells. In one of three patients, MDS can progress into AML, a rapidly growing cancer of bone marrow cells.1
About the Zella 102 Study
The Zella 102 study is an open-label, dose-escalation Phase 1b/2 study evaluating the safety and efficacy of alvocidib, when administered in sequence after either decitabine or azacitidine, in patients with previously untreated MDS and patients with MDS who have received fewer than six cycles of treatment with hypomethylating agents. The primary objective of the Phase 1b portion of the study is to determine the maximum tolerated dose and recommended Phase 2 dose of alvocidib, when administered in these regimens. Secondary objectives are to determine the complete response rate and if treatment with alvocidib, administered in sequence after decitabine or azacitidine, results in improvements in transfusion dependence and/or hemoglobin level.
The primary objective of the Phase 2 portion of the study will be to determine the objective response rate of alvocidib, when administered to untreated patients with de novo or secondary MDS in sequence after a hypomethylating agent, using revised International Working Group (IWG) criteria.
The trial is being conducted at sites in the United States. Additional information on this trial, including comprehensive inclusion and exclusion criteria, can be accessed at http://www.ClinicalTrials.gov(NCT03593915).
About Alvocidib
Alvocidib is an investigational small molecule inhibitor of cyclin-dependent kinase 9 (CDK9) currently being evaluated in the Phase 2 studies Zella 202, in patients with acute myeloid leukemia (AML) who have either relapsed from or are refractory to venetoclax in combination with decitabine or azacitidine (NCT03969420) and Zella 201, in patients with relapsed or refractory MCL-1 dependent AML, in combination with cytarabine and mitoxantrone (NCT02520011). Alvocidib is also being evaluated in Zella 101, a Phase 1 clinical study evaluating the maximum tolerated dose, safety and clinical activity of alvocidib in combination with cytarabine and daunorubicin (7+3) in newly diagnosed patients with AML (NCT03298984), and Zella 102, a Phase 1b/2 study in patients with myelodysplastic syndromes (MDS) in combination with decitabine or azacitidine (NCT03593915). In addition, alvocidib is being evaluated in a Phase 1 study in patients with relapsed or refractory AML in combination with venetoclax (NCT03441555).
About CDK9 Inhibition and MCL-1
MCL-1 is a member of the apoptosis-regulating BCL-2 family of proteins.2 In normal function, it is essential for early embryonic development and for the survival of multiple cell lineages, including lymphocytes and hematopoietic stem cells.3 MCL-1 inhibits apoptosis and sustains the survival of leukemic blasts, which may lead to relapse or resistance to treatment.2,4 The expression of MCL-1 in leukemic blasts is regulated by cyclin-dependent kinase 9 (CDK9).5,6 Because of the short half-life of MCL-1 (2-4 hours), the effects of targeting upstream pathways are expected to reduce MCL-1 levels rapidly.5 Inhibition of CDK9 has been shown to block MCL-1 transcription, resulting in the rapid downregulation of MCL-1 protein, thus restoring the normal apoptotic regulation.2
About Tolero Pharmaceuticals, Inc.
Tolero Pharmaceuticals is a clinical-stage biopharmaceutical company researching and developing treatments to improve and extend the lives of patients with hematological and oncological diseases. Tolero has a diverse pipeline that targets important biological drivers of blood disorders to treat leukemias, anemia, and solid tumors, as well as targets of drug resistance and transcriptional control.
Tolero Pharmaceuticals is based in the United States and is an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan. Tolero works closely with its parent company, Sumitomo Dainippon Pharma, and Boston Biomedical, Inc., also a wholly owned subsidiary, to advance a pipeline of innovative oncology treatments. The organizations apply their expertise and collaborate to achieve a common objective - expediting the discovery, development and commercialization of novel treatment options.
Additional information about the company and its product pipeline can be found at http://www.toleropharma.com.
Tolero Pharmaceuticals Forward-Looking Statements
This press release contains "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. The forward-looking statements in this press release are based on management's assumptions and beliefs in light of information presently available, and involve both known and unknown risks and uncertainties, which could cause actual outcomes to differ materially from current expectations. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.
View original content:http://www.prnewswire.com/news-releases/tolero-pharmaceuticals-announces-expansion-of-the-zella-102-study-in-patients-with-intermediate-and-high-risk-myelodysplastic-syndromes-mds-301058970.html
SOURCE Tolero Pharmaceuticals, Inc.
- The Stem Cell Debate: Is it Over? - University of Utah - November 24th, 2022
- Stem Cells in Use - University of Utah - November 6th, 2022
- Genes and Addiction - University of Utah - November 6th, 2022
- The History of Cloning - University of Utah - October 29th, 2022
- Brain-Like Organoids Grown in a Dish Provide Window into Autism - University of Utah Health Care - October 13th, 2022
- Brain Dissections: Neuroanatomy Video Lab - University of Utah - October 4th, 2022
- Calendar of events, awards and opportunities - ASBMB Today - August 22nd, 2022
- This Man Set the Record for Wearing a Brain-Computer Interface - WIRED - August 22nd, 2022
- STEMTECH CORPORATION Partners with VERB in Launching Interactive Video and Livestreaming Sales Enablement Apps to Strengthen Direct Sales Channel -... - July 27th, 2022
- Cloning and Stem Cells | Biological Principles - July 3rd, 2022
- Effect of tensile frequency on osteogenic differentiation | IJGM - Dove Medical Press - July 3rd, 2022
- The White Rim - Around Again - Cycling West - Cycling Utah - June 22nd, 2022
- Efficacy and Safety of Sintilimab in Combination with Concurrent Chemo | CMAR - Dove Medical Press - June 22nd, 2022
- Sen. Orrin Hatch's legacy tracks the GOP's evolution on health - NPR - May 2nd, 2022
- Stem Cell Quick Reference - University of Utah - October 28th, 2021
- Fasting boosts stem cells regenerative capacity | MIT ... - October 5th, 2021
- US stem cell clinics boomed while FDA paused crackdown ... - October 5th, 2021
- Learn how to remove unwanted fat with procedures beyond liposuction - ABC 4 - July 21st, 2021
- A $50,000 Helmet Can Read User's Mind. And It's Ready - NDTV - June 23rd, 2021
- Is the Tooth Fairy Real? the Origin Story to the Tooth Fairy, and Why It Is a Story Commonly Told Today - Digital Journal - June 23rd, 2021
- Childrens book, Olivias Tower: The Building Power of Cells - ABC 4 - October 13th, 2020
- New Stem Cell Injury Lawsuit Filed StemVive & Utah Cord Bank - June 15th, 2020
- Surplus antioxidants are pathogenic for hearts and skeletal muscle - The Mix - May 15th, 2020
- On the Road to 3-D Printed Organs - The Scientist - March 2nd, 2020
- These Vaginas Evolved to Fight the Penis, Not Accommodate It - VICE - January 5th, 2020
- 5 Innovations From the Science of Senses Now. Powered by - Now. Powered by Northrop Grumman. - December 8th, 2019
- Brainstorm Cell Therapeutics Inc. (BCLI) and PolarityTE Inc. (NASDAQ:PTE) Contrasting side by side - The Broch Herald - December 8th, 2019
- Merus N.V. (MRUS) and PolarityTE Inc. (NASDAQ:PTE) Contrasting side by side - The Broch Herald - November 29th, 2019
- Intermountain to open new center for pediatric precision medicine - Healthcare IT News - November 29th, 2019
- Orthopedic Stem Cell Therapy in Utah for Painful Joints - September 7th, 2019
- Umbilical Cord Stem Cell Review: StemVive from Utah Cord ... - April 27th, 2019
- Mutation Generation & Detection HSC Cores: Home - March 10th, 2019
- Utah Stem Cells - Salt Lake City, UT - Yelp - January 4th, 2019
- Stem Cells for Hair in Park City, Utah Docere Medical - December 9th, 2018
- PRP vs Stem Cell Injections | Southwest Spine and Pain Center - September 24th, 2018
- Stem Cell Joint Regeneration | Utah Stem Cells - July 26th, 2018
- Transgenic Gene-Targeting Mouse Facility HSC Cores: Home - July 8th, 2018
- About Us | Utah Stem Cells - June 22nd, 2018
- Fasting for 24 hours regenerates stem cells, study finds ... - June 18th, 2018
- Adult Stem Cell Therapy in Utah Docere Clinics - October 1st, 2017
- Utah Stem Cells - Cottonwood Heights, UT | Groupon - September 26th, 2017
- COLUMN: Let's make biological warfare a crime - Journal Gazette and Times-Courier - September 2nd, 2017
- FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - Utah Public Radio - August 30th, 2017
- Utah family sets up campground in Rexburg to fight cancer - Rexburg Standard Journal - August 25th, 2017
- Scientists Discover New Hair Growth Technique Using Stem Cells - TrendinTech - August 18th, 2017
- Stem cell researchers discover promising lead in quest for hair regrowth - PhillyVoice.com - August 18th, 2017
- UCLA scientists identify a new way to activate stem cells to make hair grow - UCLA Newsroom - August 18th, 2017
- Adult Stem Cells' Role in Disease Management and Anti-Aging - August 12th, 2017
- Fast facts about cloning - WPSD Local 6 - August 12th, 2017
- Reinventing tissue regeneration, one layer at a time - MedCity News - August 12th, 2017
- Q Therapeutics Expands Board of Directors With Appointment of Dr. Tom Parks as Independent Member - Marketwired (press release) - August 12th, 2017
- Stem Cell Therapy for Knees- Advanced Techniques - December 6th, 2016
- Utah Stem Cells - Sports Medicine - 7430 Creek Rd, Sandy ... - December 3rd, 2016
- Biochemistry - | University of Utah - November 26th, 2016
- medicine.utah.edu - University of Utah School of Medicine - November 23rd, 2016
- Home - Department of Chemistry - The University of Utah - November 23rd, 2016
- Stem Cell Quick Reference - Learn Genetics - November 18th, 2016
- Amniotic Stem Cell Therapy in Salt Lake City, Park City Utah - August 22nd, 2016
- Curriculum Index - University of Utah - October 19th, 2015
- Actionbioscience | Stem Cells for Cell-Based Therapies - May 4th, 2015
- Heart Stem Cell Therapy | University of Utah Health Care - April 18th, 2015
- Hyperbaric oxygen therapy and its benefits on wound treatment - March 11th, 2015
- Stem Cell Collection - University of Utah Internal ... - March 10th, 2015
- What are stem cells? - Craig A. Kohn | TED-Ed - December 12th, 2014
- What Are Stem Cells? - CSA - November 15th, 2014
- Tennis: Rafael Nadal to receive stem cell treatment for ... - November 12th, 2014
- Stem Cells in India | Stem Cell Therapy in India | Quality ... - October 16th, 2014
- Teacher Guide: Stem Cell Multimedia Project ACTIVITY OVERVIEW - September 27th, 2014
- Utah Cord Bank | 1-877-UCB-STEM | - September 27th, 2014
- Utah Stem Cell Therapy | Stem Cell Treatments - August 22nd, 2014
- Heart Stem Cell Therapy - - - University of Utah Health ... - August 22nd, 2014